Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 339-353

  Biesemeier, Antje ^a   Eibl, Oliver ^a   Eswara, Santhana ^b   Audinot, Jean Nicolas ^b   Wirtz, Tom ^b   Pezzoli, Gianni ^c   Zucca, Fabio A ^d   Zecca, Luigi ^d   Schraermeyer, Ulrich ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY   (Luxembourg)

^c PARKINSON INSTITUTE   (Italy)

^d CNR   (Italy)

Author keywords

analytical electron microscopy; correlative microscopy; nano secondary ion mass spectrometry; substantia nigra neuromelanin; trace metals

Indexed keywords

NEUROMELANIN; PHOSPHOLIPID;

AGED; ARTICLE; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MICROANALYSIS; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84979026657     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13648     Document Type: Article

References (53)

1. Audinot J. N., Cabin-Flaman A., Philipp P., Legent G., Wirtz T. and Migeon H. N. (2011) NanoSIMS50 imaging of thin samples coupled with neutral cesium deposition. Surf. Interface Anal. 43, 302–305.
2. Biesemeier A., Eibl O. and Schraermeyer U. (2011a) Chemical composition of melanosomes, lipofuscin and melanolipofuscin granules of human RPE tissues. Exp. Eye Res. 93, 29–39.
3. Biesemeier A., Eibl O. and Schraermeyer U. (2011b) Quantitative chemical analysis of ocular melanosomes in stained and non-stained tissues. Micron 42, 461–470.
4. Biesemeier A., Yoeruek E., Eibl O. and Schraermeyer U. (2015) Iron accumulation in Bruch's membrane and melanosomes of donor eyes with age-related macular degeneration. Exp. Eye Res. 137, 39–49.
5. Bohic S., Murphy K., Paulus W., Cloetens P., Salome M., Susini J. and Double K. (2008) Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal. Chem. 80, 9557–9566.
6. Braidy N., Poljak A., Marjo C., Rutlidge H., Rich A., Jayasena T., Inestrosa N. C. and Sachdev P. (2014) Metal and complementary molecular bioimaging in Alzheimer's disease. Front. Aging Neurosci. 6, 138.
7. Bush W. D., Garguilo J., Zucca F. A., Albertini A., Zecca L., Edwards G. S., Nemanich R. J. and Simon J. D. (2006) The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc. Natl Acad. Sci. USA 103, 14785–14789.
8. Cebrián C., Zucca F. A., Mauri P. et al. (2014) MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat. Commun. 5, 3633.
9. Connor J. R., Menzies S. L., St Martin S. M. and Mufson E. J. (1990) Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27, 595–611.
10. Connor J. R. and Menzies S. L. (1995) Cellular management of iron in the brain. J. Neurol. Sci. 134 Suppl:33–44.
11. Dexter D. T., Wells F. R., Agid F., Agid Y., Lees A. J., Jenner P. and Marsden C. D. (1987) Increased nigral iron content in postmortem parkinsonian brain. Lancet 2, 1219–1220.
12. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P. and Marsden C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830–1836.
13. Dzierzega-Lecznar A., Kurkiewicz S., Stepien K., Chodurek E., Riederer P. and Gerlach M. (2006) Structural investigations of neuromelanin by pyrolysis-gas chromatography/mass spectrometry. J. Neural. Transm. 113, 729–734.
14. Ehringer H. and Hornykiewicz O. (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin. Wochenschr. 38, 1236–1239.
15. Eibl O., Schultheiss S., Blitgen-Heinecke P. and Schraermeyer U. (2006) Quantitative chemical analysis of ocular melanosomes in the TEM. Micron 37, 262–276.
16. Engelen M., Vanna R., Bellei C., Zucca F. A., Wakamatsu K., Monzani E., Ito S., Casella L. and Zecca L. (2012) Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PLoS ONE 7, e48490.
17. Faucheux B. A., Martin M. E., Beaumont C., Hauw J. J., Agid Y. and Hirsch E. C. (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86, 1142–1148.
18. Good P. F., Olanow C. W. and Perl D. P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593, 343–346.
19. Hirsch E. C., Brandel J. P., Galle P., Javoy-Agid F. and Agid Y. (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56, 446–451.
20. Hoppe P., Cohen S. and Meibom A. (2013) NanoSIMS: technical aspects and applications in cosmochemistry and biological geochemistry. Geostand. Geoanal. Res. 37, 111–154.
21. INCA (2001) The microanalysis Suite, Issue 18b. Oxford Instruments Analytical Limited.
22. Ito S. and Fujita K. (1985) Microanalysis of eumelanin and pheomelanin in hair and melanomas by chemical degradation and liquid chromatography. Anal. Biochem. 1, 527–536.
23. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D. and Youdim M. B. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59, 1168–1171.
24. Jellinger K. A., Kienzl E., Rumpelmaier G., Paulus W., Riederer P., Stachelberger H., Youdim M. B. and Ben-Shachar D. (1993) Iron and ferritin in substantia nigra in Parkinson's disease. Adv. Neurol. 60, 267–272.
25. Jimbow K., Miyake Y., Homma K., Yasuda K., Izumi Y., Tsutsumi A. and Ito S. (1984) Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanoma. Cancer Res. 44, 1128–1134.
26. Kastner A., Hirsch E. C., Lejeune O., Javoy-Agid F., Rascol O. and Agid Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59, 1080–1089.
27. Kienzl E., Puchinger L., Jellinger K., Linert W., Stachelberger H. and Jameson R. F. (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J. Neurol. Sci. 134(Suppl), 69–78.
28. McRae R., Bagchi P., Sumalekshmy S. and Fahrni C. J. (2009) In situ imaging of metals in cells and tissues. Chem. Rev. 109, 4780–4827.
29. Milardi D. and Rizzarelli E. (2011) Neurodegeneration: metallostasis and proteostasis. RSC Publishing, Cambridge. Print. ISBN 978-1-84973-050-1; DOI:10.1039/9781849733014.
30. Mueller C. W., Weber P. K., Kilburn M., Hoeschen C., Kleber M. and Pett-Ridge J. (2013) Advances in the Analysis of Biogeochemical Interfaces: NanoSIMS to Investigate Soil Microenvironments, in Advances in Agronomy, Vol. 121 (Sparks D. L., ed), pp. 1–46. Academic Press, Burlington.
31. Oakley A. E., Collingwood J. F., Dobson J., Love G., Perrott H. R., Edwardson J. A., Elstner M. and Morris C. M. (2007) Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68, 1820–1825.
32. Pakkenberg B., Møller A., Gundersen H. J., Mouritzen Dam A. and Pakkenberg H. (1991) The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J. Neurol. Neurosurg. Psychiatry 54, 30–33.
33. Que E. L., Domaille D. W. and Chang C. J. (2008) Metals in neurobiology: probing their chemistry and biology with molecular imaging. Chem. Rev. 108, 1517–1549.
34. Quintana C., Wu T. D., Delatour B., Dhenain M., Guerquin-Kern J. L. and Croisy A. (2007) Morphological and chemical studies of pathological human and mice brain at the subcellular level: correlation between light, electron, and nanosims microscopies. Microsc. Res. Tech. 70, 281–295.
35. Reimão S., Pita Lobo P., Neutel D. et al. (2015) Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. Eur. J. Neurol. 22, 540–546.
36. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Jellinger K. and Youdim M. B. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515–520.
37. Rouault T. A. (2013) Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat. Rev. Neurosci. 14, 551–564.
38. Samuelson D. A., Smith P., Ulshafer R. J., Hendricks D. G., Whitley R. D., Hendricks H. and Leone N. C. (1993) X-ray microanalysis of ocular melanin in pigs maintained on normal and low zinc diets. Exp. Eye Res. 56, 63–70.
39. Sulzer D., Bogulavsky J., Larsen K. E. et al. (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl Acad. Sci. USA 97, 11869–11874.
40. Sulzer D., Mosharov E., Talloczy Z., Zucca F. A., Simon J. D. and Zecca L. (2008) Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 106, 24–36.
41. Wakamatsu K., Fujikawa K., Zucca F. A., Zecca L. and Ito S. (2003) The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 86, 1015–1023.
42. Ward R. J., Zucca F. A., Duyn J. H., Crichton R. R. and Zecca L. (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13, 1045–1060.
43. Wirtz T., Philipp P., Audinot J. N., Dowsett D. and Eswara S. (2015) High-resolution high-sensitivity elemental imaging by secondary ion mass spectrometry: from traditional 2D and 3D imaging to correlative microscopy. Nanotechnology 26, 434001.
44. Zecca L., Mecacci C., Seraglia R. and Parati E. (1992) The chemical characterization of melanin contained in substantia nigra of human brain. Biochim. Biophys. Acta 1138, 6–10.
45. Zecca L., Shima T., Stroppolo A., Goj C., Battiston G. A., Gerbasi R., Sarna T. and Swartz H. M. (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73, 407–415.
46. Zecca L., Costi P., Mecacci C., Ito S., Terreni M. and Sonnino S. (2000) Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 74, 1758–1765.
47. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A. and Tampellini D. (2002) The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510, 216–220.
48. Zecca L., Stroppolo A., Gatti A. et al. (2004a) The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl Acad. Sci. USA 101, 9843–9848.
49. Zecca L., Youdim M. B., Riederer P., Connor J. R. and Crichton R. R. (2004b) Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863–873.
50. Zecca L., Bellei C., Costi P. et al. (2008a) New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl Acad. Sci. USA 105, 17567–17572.
51. Zecca L., Wilms H., Geick S. et al. (2008b) Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol. 116, 47–55.
52. Zhang W., Phillips K., Wielgus A. R. et al. (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox. Res. 19, 63–72.
53. Zucca F. A., Segura-Aguilar J., Ferrari E., Munoz P., Paris I., Sulzer D., Sarna T., Casella L. and Zecca L. (2015) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog. Neurobiol. pii: S0301-0082(15)00101-X. doi: 10.1016/j.pneurobio.2015.09.012.